

Prospective Analysis of 55 Cases of Tuberculosis Meningitis (TBM) in North India

HARSIMRAN KAUR¹, KUSUM SHARMA², MANISH MODI³, AMAN SHARMA⁴, SATYAWATI RANA⁵, NIRANJAN KHANDELWAL⁶, SUDESH PRABHAKAR⁷, SUBHASH VARMA⁸

ABSTRACT

Introduction: To assess the clinical profile, laboratory and neuroimaging data of adult tuberculous meningitis (TBM) patients and to determine the predictors of mortality.

Materials and Methods: A total of 55 TBM patients and 60 controls were enrolled in this prospective study. Detailed clinical, radiological, biochemical and microbiological evaluation was performed.

Statistical Analysis: Done using SPSS 15.0 for Windows. P value of <0.05 was considered to be significant.

Results: 61.8% were males and majority of the study subjects belonged to age group of 21-40 years. Duration of symptoms in all cases was >14 days and commonly included fever, headache, neck rigidity, altered sensorium and vomiting. Biochemical features of cerebrospinal fluid (CSF) showed significant results where

94.5%, 85.45%, 83.63% and 81.81% of patients showed CSF sugar levels <2/3 corresponding blood sugar, proteins >100mg%, CSF total leucocyte count of >20 cells/mm³ and ADA >9.5IU/L respectively while neuroimaging revealed hydrocephalus, basal exudates and meningeal enhancement as significant findings. More than half of TBM patients presented in stage II of disease and overall mortality was 43.63%. A model for prediction of mortality in TBM cases was framed which included variables of age >40 years, past history of tuberculosis (TB), presence of basal exudates and hydrocephalus.

Conclusion: TBM is a serious extrapulmonary form of TB and should arise suspicion in mind of clinician based on clinical, laboratory and radiologic results. Further, a model for prediction of mortality in such patients may be helpful for early intervention and better prognosis.

Keywords: Clinical, India, Laboratory parameters, Neuroimaging, Predictors of mortality, Tuberculous meningitis

INTRODUCTION

Tuberculosis meningitis (TBM) is a serious public health problem in developing countries as it leads to significant mortality and residual neurological sequelae. The estimated mortality due to TBM in India is 1.5 per 100,000 population [1]. Despite being an endemic country for TB, data regarding clinical, radiological and laboratory (biochemical and microbiological) parameters and final outcome of adult TBM patients is sparse in India. Analysis of such variables in various countries has shown association of various factors with the prognosis of the disease like age, stage of disease, level of consciousness, presence of extraneural TB, isolation of *Mycobacterium tuberculosis* from CSF, biochemical studies and hydrocephalus [2-4]. The availability of such data in a high burdened developing country like India may help in prediction of the prognosis of such patients and help in early intervention of preventive measures to improve the subsequent outcome of the patients. The present work was planned as a prospective study to assess the clinical profile, laboratory values and neuroimaging features of adult TBM patients and to find out predictors of mortality in these patients so as to frame a model in future which will help in predicting the prognosis of the patients.

MATERIALS AND METHODS

This prospective study was conducted over seven months from August 2010 to February 2011 in Department of Medical Microbiology and Neurology of our tertiary care referral centre in North India. The study was approved by Institute Ethics Committee and was conducted after taking informed consent from the patients. A total of 55 cases of age >12 y diagnosed as TBM based on clinical criteria were included in the study and were divided into confirmed and suspected group according to criteria as given by Ahuja et al., [5]. All these cases fulfilled Thwaites' index (score of 4 or less suggests TBM) [6]. Patients were also clinically divided

into 3 stages using Medical Research Council staging system [7]. The control group included 60 patients with differential diagnosis of TBM in which 30 cases of meningitis like bacterial other than *Mycobacterium tuberculosis* (11), viral (15) and fungal (4) meningitis and rest 30 included patients of non-infectious illness of central nervous system as described previously. Detailed clinical history including age and sex was taken emphasising on presence of fever, headache, vomiting, altered sensorium in a prescribed proforma. Patients were clinically evaluated for signs of meningeal irritation, raised intracranial pressure, cranial nerve deficits, focal neurological deficits and evidence of TB elsewhere in the body. Laboratory parameters included CSF cell count and levels of protein, glucose and adenosine deaminase (ADA). CSF evaluation for *Mycobacterium tuberculosis* was done by multiplex PCR using two primers, i.e. IS6110 and MPB64. The radiological details of contrast enhanced CT brain, MRI brain, CT chest, CT abdomen were also noted. The response to treatment was judged by gain of weight, appetite and improvement of behaviour. The cases were treated with four drug regimen of antitubercular drugs according to the national programme in India.

STATISTICAL ANALYSIS

Statistical analysis was done using SPSS 15.0 for Windows. Tests used included Student's t-test, Fischer's exact test and Chi square test. Univariate and multivariate analysis was done to find out the predictors of mortality. Odds ratio was used to denote the risk of various factors. p-value of <0.05 was considered to be significant.

RESULTS

The 55 TBM cases were divided into confirmed (n=9) and suspected (n=46) group. The suspected cases were further classified into highly probable (n=4), probable (n=39) and possible (n=3) cases. Four

patients were HIV positive (7.27%) and belonged to the confirmed TBM group.

Age and Gender

Among 55 patients, 61.8% patients were males and 38.2% were females. 45.5% of the patients were of the age group between 21-40 years while 21.8% and 32.7% patients belonged to age group ≤ 20 y and ≥ 40 y respectively. The mean age of TBM patients and control group was 36.42 ± 16.20 y and 40.88 ± 17.57 y respectively.

Signs & Symptoms, Sites of Involvement and Comorbidities

The duration of symptoms in all TBM cases was > 14 d (mean of 16 d). The most common symptoms included fever (90.9%), headache (72.7%), neck rigidity (67.3%), altered sensorium (65.5%) and vomiting (54.5%). The most commonly involved cranial nerve was 6th nerve (9.1%). The symptoms of fever, headache, vomiting, seizures, anorexia and neck rigidity were found to be significantly high in TBM patients ($p < 0.05$) [Table/Fig-1]. The most common presentation of extraneural TB was miliary distribution (16%) followed by pulmonary involvement, lymphadenitis and abdominal TB.

Cerebrospinal Fluid Characteristics

Cell Count, Protein and Glucose Levels

In TBM group, mean CSF cell count was 303.21 cells /mm³, mean CSF protein and glucose were 170.2 mg/dl and 38.3 mg/dl respectively. Statistically significant results were obtained between cases and controls when CSF features of protein > 100 mg%, cells > 20 /mm³ & CSF sugar $< 60\%$ of corresponding blood sugar were compared [Table/Fig-1].

	TBM patients	Control group	P value
Clinical features			
Fever	50 (90.9%)	41(68.3%)	0.003
Headache	40 (72.7%)	28(46.7%)	0.008
Vomiting	30 (54.5%)	21(35.0%)	0.040
Seizures	13(23.6%)	14(23.3%)	1.000
Anorexia	31(56.4%)	4(6.7%)	< 0.001
Coma	10(18.18)	4(6.66%)	0.0860
Altered sensorium	36 (65.5%)	34(56.7%)	0.347
Neck rigidity	37 (67.3%)	19(31.7%)	< 0.001
Cranial nerve palsy	8(14.5%)	3(5.0%)	0.114
6 th nerve	5 (9.1%)	0 (0%)	0.023
7 th	4 (7.3%)	2 (3.33%)	0.424
3 rd nerve	1 (1.8%)	1(1.7%)	1.000
5 th	1 (1.8%)	0(0%)	0.478
Hemiparesis/ Hemiplegia	8 (14.5%)	7(11.66%)	0.783
Evidence of extra neural tuberculosis	16 (29.1%)	0(0%)	< 0.001
History of TB	9(16.4%)	0(0%)	< 0.001
CSF characteristics			
Protein > 100 mg%	47(85.45%)	18(30%)	< 0.001
CSF TLC > 20 cells/mm ³	46(83.63%)	18(30%)	< 0.001
CSF sugar $< 2/3$ CBS	52 (94.5%)	42 (70%)	0.0006

[Table/Fig-1]: Clinical features and CSF characteristics of study subjects


ADA Levels

Mean CSF ADA value in TBM patient was 14.44 ± 6.91 IU/L, which was significantly higher than the control group having value of 3.156 ± 2.253 IU/L ($p < 0.001$). Within the confirmed group, mean value was 20.11 ± 10.25 IU/L while highly probable, probable and possible TBM groups had values of 13.286 ± 5.45 , $13.905 \pm$

5.68 and 9.333 ± 5.13 IU/L respectively. Mean CSF ADA value in infectious meningitis other than TBM was 3.125 ± 1.907 IU/L and its subgroup pyogenic meningitis had value of 3.142 ± 1.69 IU/L. The TBM patients had significantly higher CSF ADA levels as compared to the control group ($p=0.014$). A cut off value of 9.5 IU/L showed 83.3% sensitivity and 99.98% specificity by receiver operating characteristic (ROC) curve analysis [Table/Fig-2]. Using this cut off, 81.81% TBM cases showed significant results ($p < 0.001$). All the patients in confirmed and possible TBM group had ADA values > 9.5 IU/L while the highly probable group and the probable group had 75% and 79.5% patients with ADA > 9.5 IU/L.

Microbiological Diagnosis

Out of the 55 CSF samples from TBM patients, 2 were positive in Ziehl Neelsen smear (5.55%) and 12 (21.8%) were positive for



[Table/Fig-2]: ROC curve for cut off of ADA

Category	Stage (total number)	Responded	Died (Mortality)
Confirmed (n=9)	Stage I (2)	1	1
	Stage II (3)	2	1
	Stage III (4)	0	4
	Total	3(33.33%)	6 (66.67%)
Suspected (n=46)	Stage I (5)	4	1
	Stage II (25)	15	10
	Stage III (16)	9	7
	Total	28 (60.9%)	18 (39.1%)
Highly probable (n=4)	Stage I (0)	0	0
	Stage II (3)	2	1
	Stage III (1)	0	1
Total	2 (50%)	2(50%)	
Probable (n=39)	Stage I (5)	4	1
	Stage II (20)	13	7
	Stage III (14)	8	6
	Total	25(64.10%)	14(35.89%)
Possible (n=3)	Stage I (0)	0	0
	Stage II (2)	0	2
	Stage III (1)	1	0
	Total	1 (33.33%)	2(66.67%)
Grand total		28+3=31	18+6=24

[Table/Fig-3]: Category wise staging of patients and their outcome

Mycobacterium tuberculosis in culture (LJ and BACTEC MGIT 960). Multiplex PCR was positive in 45 patients (including HIV positive cases) out of total 55 TBM cases, thereby showing a sensitivity of 81.81%. None of these tests were positive in the control group, thus showing specificity of 100%.

Neuroimaging Findings

CT/MRI findings were suggestive of TBM in 34 patients (61.8%) and the common findings included hydrocephalus (24%), presence of basal exudates (22%), meningeal enhancement (20%), presence of tuberculomas (7%) and presence of infarcts (3.6%). 88.88% of confirmed TBM cases (including HIV positive cases) had the suggestive findings. The presence of hydrocephalus, basal exudates and meningeal enhancement was significantly higher in TBM group ($p < 0.05$).

Staging of TBM and Outcome

50.9% of the patients belonged to the stage II while 36.4% (including 4 HIV positive cases) were in stage III followed by 12.7% patients who were in stage I. The confirmed cases mostly presented in stage III while most of the suspected patients were in stage II [Table/Fig-3]. Mortality was highest in confirmed cases (66.67%) while in suspected cases it was 39.1%. There was increase in mortality as the stage of disease increased; 28.57%, 39.29% and 55% in stage I, II and III respectively. Total mortality seen in TBM cases was 43.63% which is high because most of the patients presented in later stages of TBM.

Predictors of Mortality

A total of 24 patients (six confirmed and 18 suspected cases) died due to the disease which included all HIV positive cases. The mean age of these patients was 42.45 years and the male to female ratio was 3:1 [Table/Fig-4]. Univariate analysis showed age ≥ 40 year, loss of appetite, loss of weight, evidence of extraneural TB, past history of TB and presence of basal exudates and hydrocephalus in neuroimaging as predictors of mortality in TBM patients [Table/Fig-5]. The factors which were not associated with mortality included clinical features of fever, vomiting, headache, neck stiffness, seizure, altered sensorium, behavioural disturbances, cranial nerve palsies and stage of disease presentation; neuroimaging features of tuberculomas and meningeal enhancement; CSF biochemical analysis findings and microbiological investigation of multiplex PCR. Multinomial logistic regression of the factors revealed age ≥ 40 year ($p=0.03$), past history of TB ($p=0.008$), presence of basal exudates ($p=0.009$) and hydrocephalus ($p=0.025$) in neuroimaging as significant risk factors for mortality in TBM patients.

DISCUSSION

TBM needs to be diagnosed and treated early as it is associated with high mortality and severe neurological sequelae especially in endemic countries like India. Nonspecific symptoms of TBM pose a challenge for the accurate timely diagnosis [8]. The study was carried out to find out the demographics of the disease and factors associated with outcome of the disease in adult TBM patients in northern region of India. 7.27% of the cases were co-infected with HIV in the present study. The data regarding the prevalence of TBM in HIV is scarce and scattered. In a study by Karande et al., in children <12 y of age in India, 6.5% TBM patients were reported have HIV coinfection [9].

The age distribution of the test and control groups was well matched in the present study. The age distribution is similar to study by Thwaites et al., where median age was 34 y in cases and 41 y in controls [10]. In another study, median age of cases was 22 y and that of controls was 24.5 y [11]. The disease was found to be more common in males. No significant difference in sex ratio

Clinical profile	Total 24 deaths	% of patients having respective features
Fever	22	91.6%
Headache	16	66.66%
Vomiting	12	50%
Seizures	8	33.33%
Anorexia	17	70.8%
Altered sensorium	18	75%
Neck rigidity	17	70.8%
Cranial nerve Palsy	3	12.5%
Hemiparesis/ Hemiplegia	2	8.33%
Evidence of extra neural tuberculosis	11	45.8%
CSF profile		
CSF sugar $<2/3$ CBS	24	100%
Protein >100 mg%	21	87.5%
CSF TLC >20 cells/mm ³	21	87.5%
ADA >9.5 IU/l	19	79.2%
Neuroimaging	19	79.2%
Hydrocephalus (communicating or non communicating)	9	37.5%
Basal exudates	9	37.5%
Meningeal enhancement	5	20.8%
Tuberculomas	5	20.8%
Infarcts	1	4.2%

[Table/Fig-4]: Clinical profile of 24 TBM patients who expired

Mortality in	Number	Mortality in	Number	p- value	OR (95% CI)	Risk ratio
Age ≥ 40 years	15/21	Age <40 years	9/34	0.001	6.94 (2.05-23.41)	2.69
LOA	17/31	No LOA	7/24	0.05	2.949 (0.95-9.12)	1.88
LOW	18/32	No LOW	6/23	0.02	3.64 (1.13-11.66)	2.15
EX TB	11/16	No EX TB	13/39	0.01	4.4 (1.26-15.34)	2.06
H/O TB	8/9	No H/O TB	16/46	0.003	15 (1.72-130.8)	2.55
Basal exudates	9/12	No basal exudates	15/43	0.01	5.6 (1.31-23.85)	2.15
Hydrocephalus	9/13	No hydrocephalus	15/42	0.03	4.05 (1.06-15.4)	1.93

[Table/Fig-5]: Predictors of mortality in TBM patients

LOA-loss of appetite, LOW- loss of weight, EX TB- evidence of extraneural TB, H/O TB- History of TB

was observed between cases and controls in the present study. The clinical picture of TBM is hard to differentiate from other types of meningitis. There are certain features like long history of illness (>5-6 d) which predict TBM [8,10,12]. In our study, all the cases had history of at least 14 d including fever (90.9%), headache (72.7%) and vomiting (54.5%). The triad of these symptoms was present in 60% of the patients. The occurrence of these symptoms was similar or higher as compared to earlier studies [1,8,13, 14]. This may be due to strict inclusion criteria of fever and headache in study group. The incidence of seizures was slightly higher in this study and that of hemiparesis, cranial nerve abnormalities and presence of extraneural TB manifestations were lower as compared with the earlier studies [8,10]. The most common cranial nerve involved was the 6th nerve (9%) which is consistent with the findings of earlier studies where 6th nerve has been reported to be most commonly involved in TBM [15]. Neck rigidity seen in different studies ranged from 18% to 91% [8,10]. In the present study, it was found out to be 67.3% thus comparable with the earlier studies. The presence of neck rigidity, extraneural TB and past history of TB were statistically significant when compared with the control group. Patients were clinically divided into 3 stages using Medical Research Council staging system [7]. Maximum patients were in stage II (n=28) followed by stage III (n=20) and stage I (n=7). Similar staging has been done in earlier studies also [16]. Higher number of stage II and stage III TBM patients in our study may be explained by the fact that ours is a tertiary care institute and patients are usually referred here for management from peripheral hospitals. The HIV positive cases had similar symptoms as HIV negative patients although they presented in later stage of disease and had higher frequency of extraneural presentation as reported earlier [17]. In a retrospective study conducted in Turkey, 160 cases of TBM were evaluated for epidemiological, clinical, laboratory and neuroimaging features [18]. The commonest clinical features were headache, fever, vomiting and neck stiffness as seen in our study while 63% patients presented in stage II and 21% in stage III. However, culture positivity was high in the study (39.9%).

The CSF biochemical picture is consistent with the usual observation of CSF findings suggestive of TBM seen in various studies also [8,19]. In the study carried out by Christensen et al., 86% had elevated protein values, 90% had elevated WBC count and 50% patients had CSF: blood glucose ratio of <0.33 [8]. In many review articles, the CSF picture has been said to be having pleocytosis of more than 20 cells/mm³, proteins >100mg/dl and CSF sugar less than 60% of corresponding blood sugar [15]. The difference in the mean CSF ADA values between TBM patients and Non TBM infectious meningitis was also found to be statistically significant. (p=0.014). The cut off value of 9.5 IU/L was crossed by 81.81% of the cases as compared to the controls where only one patient (1/60, 1.66%) of Japanese encephalitis had this higher value. This finding was significant with a p-value of <0.001. Similar finding has been reported in earlier studies also [20,21]. Earlier, various studies reported the reliability of CSF ADA activity in TBM patients using different cut off values [19]. Our results are in accordance with study of Gambhir et al., who found mean CSF-ADA activities in TBM patients significantly higher (9.6 ± 4.1 IU/L) than those suffering from viral meningitis or non-infectious etiology [22]. Moghtaderi et al., found mean CSF-ADA activity in TBM group (23.05±13.1 IU/L) to be significantly higher than in the CSF from non-TBM (pyogenic plus viral) infectious meningitis patients (9.39±5.18 IU/L) [23]. The highest accuracy was observed when cut-off value of 10.5 IU/L was considered. The sensitivity and specificity of the test to differentiate TBM from non-TBM was found to be 81% and 86% respectively. Karsen et al., found with cut-off value of 12.35 IU/L for differential diagnosis of TBM and pyogenic meningitis, sensitivity was 92% and specificity was 100% [24]. However, cut-off level of 11 IU/L for differentiating between TB and non-TB by applying ROC analysis was found to have sensitivity of 92% and specificity of 90%. Gupta

et al., indicated that ADA level in CSF with 10 IU/L as a cutoff value demonstrated 94.73% sensitivity and 90.47% specificity in differentiating TB from non-TBM [20]. Sun et al., concluded that ADA estimation with a cut off value of 9.5 IU/L in CSF was an adjunct for the differential diagnosis of TBM and non-TBM [21]. Our finding was consistent with this recent observation for using 9.5 IU/L as a cut off value.

On neuroimaging, hydrocephalus (n=13) (24%) was the most common finding observed, followed by basal exudates (n=12) (22%), meningeal enhancement (n=11) (20%) tuberculomas (n=4) (7%) and infarcts (n=3) (3.6%). Christensen et al., in his study on Danish people also found hydrocephalus as the most common finding (29%) [8]. They also had high incidence of infarcts (29%) and tuberculomas (14%). While in the immigrant population, basal meningeal enhancement (67%) was the most common finding. In various reviews, hydrocephalus and basal meningeal enhancement have been reported to be the most common finding on neuroimaging [15]. However, the most common imaging feature was tuberculomas and basal meningitis in a study conducted in Turkey [18]. Higher frequency of hydrocephalus in our institute may be due to the referral bias of tertiary care centre, as mentioned earlier.

In the present study, it was observed that with increasing stage i.e. from I to III, the number of patients who responded to treatment gradually decreased and mortality increased. Most of the cases in confirmed category belonged to stage III (44.4%) while most of the cases in suspected group belonged to stage II (54.3%). Total mortality seen in TBM cases was 43.63% which is high because most of the patients presented in later stages of TBM. All HIV positive cases died showing high rates of mortality in HIV-TBM coinfection. The mortality rate in a study in Denmark has been reported to be 19% [8]. Studies in areas of endemic TB have shown higher mortality rate (69% in South Africa and 67% in Vietnam) [25,26]. Severity of TBM at presentation serves as a good prognostic marker. This observation is in league with the previous studies which had identified the most important determinant of outcome for both survival and sequelae being the neurological stage of the disease at which treatment was started. If the treatment was started during early stages, the mortality and morbidity was low. However, in stage III the mortality was almost 50% and most of the survivors suffered from some form of neurological deficit [27,28].

Age ≥ 40 y, loss of appetite, loss of weight, evidence of extraneural TB, past history of TB and presence of basal exudates and hydrocephalus were observed as predictors of mortality in our study. In a study by George et al., age > 40 y, Glasgow coma scale (GCS) score <8, CSF protein ≤60 mg% and MRC stage III were found to be the predictors of mortality in TBM [6]. Similar to above results, a study conducted in Taiwan also showed age >60 years as an important factor associated with higher mortality [29]. Girgis et al., have shown presence of hydrocephalus to be a risk factor for poor outcome of TBM [30]. Similar to this finding we also observed higher rate of mortality in patients with hydrocephalus. Many studies have shown absence of headache as a predictor of mortality which may be due to the delay in presentation in such cases [6,29]. Such observation was not there in the present study. Delayed treatment, female gender, infarction, low CSF glucose levels, low CSF/blood glucose ratio and high CSF protein concentration are the factors which have been observed to predict mortality in TBM cases in various studies but univariate analysis in our study did not reveal such association with these variables [4,26,29,31,32].

CONCLUSION

Thus, the present study provides the epidemiological factors of TBM in adult patients in Northern India including clinical, laboratory and imaging data. Our results are comparable to various studies in developing countries. The presence of TB at sites other than CNS, associated pulmonary TB and positive imaging findings have

highlighted the importance of radiodiagnosis in our study. CSF ADA value of >9.5IU/L and multiplex PCR have shown a good sensitivity and specificity for diagnosis of TBM. It is a preliminary study with small number of study subjects. Multicentric studies regarding the issue in future may help in better exploration of the disease and associated factors. The present study may help in formulation of mortality prediction score using age>40 y, imaging findings of hydrocephalus and basal exudates and past history of TB as variables. This will improve the early implementation of stringent management therapies to save the patient.

REFERENCES

- [1] Murthy JM. Tuberculosis meningitis: the challenges. *Neurol India*. 2010;58:716-22.
- [2] Wang JT, Hung CC, Sheng WH, Wang JY, Chang SC, Luh KT. Prognosis of Tuberculosis meningitis in adults in the era of modern antiTuberculosis chemotherapy. *J Microbiol Immunol Infect*. 2002;35:215-22.
- [3] Lu CH, Chang WN, Chang HW. The prognostic factors of adult Tuberculosis meningitis. *Infection*. 2001;29:299-304.
- [4] Misra UK, Kalita J, Roy AK, Mandal SK, Srivastava M. Role of clinical, radiological, and neurophysiological changes in predicting the outcome of Tuberculosis meningitis: a multivariable analysis. *J Neurol Neurosurg Psychiatry*. 2000;68:300-03.
- [5] Ahuja GK, Mohan KK, Prasad K, Behari M. Diagnostic criteria for Tuberculosis meningitis and their validation. *Tuber Lung Dis*. 1994;75:149-52.
- [6] George EL, Iype T, Cherian A, Chandy S, Kumar A, Balakrishnan A, et al. Predictors of mortality in patients with meningeal tuberculosis. *Neurol India*. 2012;60:18-22.
- [7] British Medical Research Council. Streptomycin treatment of Tuberculosis meningitis. *Lancet*. 1948;1:582-96.
- [8] Christensen AS, Andersen AB, Thomsen VO, Andersen PH, Johansen IS. Tuberculosis meningitis in Denmark: a review of 50 cases. *BMC Infect Dis*. 2011;11:47.
- [9] Karande S, Gupta V, Kulkarni M, Joshi A, Rele M. Tuberculosis meningitis and HIV. *Indian J Pediatr*. 2005;72:755-60.
- [10] Thwaites GE, Chau TT, Stepniewska K, Phu NH, Chuong LV, Sinh DX, et al. Diagnosis of adult Tuberculosis meningitis by use of clinical and laboratory features. *Lancet*. 2002;360:1287-92.
- [11] Seth P, Ahuja GK, Bhanu NV, Behari M, Bhowmik S, Broor S, et al. Evaluation of polymerase chain reaction for rapid diagnosis of clinically suspected Tuberculosis meningitis. *Tuber Lung Dis*. 1996;77:353-57.
- [12] Kumar R, Singh SN, Kohli N. A diagnostic rule for Tuberculosis meningitis. *Arch Dis Child*. 1999;81:221-24.
- [13] Kent SJ, Crowe SM, Yung A, Lucas CR, Mijch AM. Tuberculosis meningitis: a 30-year review. *Clin Infect Dis*. 1993;17:987-94.
- [14] Farinha NJ, Razali KA, Holzel H, Morgan G, Novelli VM. Tuberculosis of the central nervous system in children: a 20-year survey. *J Infect*. 2000;41:61-68.
- [15] Cherian A, Thomas SV. Central nervous system tuberculosis. *Afr Health Sci*. 2011;11:116-27.
- [16] Newton RW. Tuberculosis meningitis. *Arch Dis Child*. 1994;70:364-66.
- [17] Thwaites GE, Duc Bang N, Huy Dung N, Thi Quy H, Thi Tuong Oanh D, Thi Cam Thoa N, et al. The influence of HIV infection on clinical presentation, response to treatment, and outcome in adults with Tuberculosis meningitis. *J Infect Dis*. 2005;192:2134-41.
- [18] Pehlivanoglu F, Yasar KK, Sengoz G. Tuberculosis meningitis in adults: a review of 160 cases. *Scientific World Journal*. 2012:169028.
- [19] Rock RB, Olin M, Baker CA, Molitor TW, Peterson PK. Central nervous system tuberculosis: pathogenesis and clinical aspects. *Clin Microbiol Rev*. 2008; 21: 243-61.
- [20] Gupta BK, Bharat A, Debapriya B, Baruah H. Adenosine Deaminase Levels in CSF of Tuberculosis Meningitis Patients. *J Clin Med Res*. 2010;2:220-24.
- [21] Sun Q, Sha W, Xiao HP, Tian Q, Zhu H. Evaluation of Cerebrospinal Fluid Adenosine Deaminase Activity for the Differential Diagnosis of Tuberculosis and NonTuberculosis Meningitis. *Am J Med Sci*. 2012; 344(2):116-21.
- [22] Gambhir IS, Mehta M, Singh DS, Khanna HD. Evaluation of CSF-adenosine deaminase activity in tubercular meningitis. *J Assoc Physicians India*. 1999;47:192-94.
- [23] Moghtaderi A, Niazi A, Alavi-Naini R, Yaghoobi S, Narouie B. Comparative analysis of cerebrospinal fluid adenosine deaminase in Tuberculosis and non-Tuberculosis meningitis. *Clin Neurol Neurosurg*. 2010;112:459-62.
- [24] Karsen H, Koruk ST, Karahocagil MK, Calisir C, Baran FC. Comparative analysis of cerebrospinal fluid adenosine deaminase activity in meningitis. *Swiss Med Wkly*. 2011;141:w13214.
- [25] Karstaedt AS, Valtchanova S, Barriere R, Crewe-Brown HH. Tuberculosis meningitis in South African urban adults. *Qjm*. 1998;91:743-47.
- [26] Torok ME, Chau TT, Mai PP, Phong ND, Dung NT, Chuong LV, et al. Clinical and microbiological features of HIV-associated Tuberculosis meningitis in Vietnamese adults. *PLoS One*. 2008;3:e1772.
- [27] Garg RK. Tuberculosis of the central nervous system. *Postgrad Med J*. 1999;75:133-40.
- [28] Sutlas PN, Unal A, Forta H, Senol S, Kirbas D. Tuberculosis meningitis in adults: review of 61 cases. *Infection*. 2003;31:387-91.
- [29] Sheu JJ, Yuan RY, Yang CC. Predictors for outcome and treatment delay in patients with Tuberculosis meningitis. *Am J Med Sci*. 2009;338:134-39.
- [30] Girgis NI, Sultan Y, Farid Z, Mansour MM, Erian MW, Hanna LS, et al. Tuberculosis meningitis, Abbassia Fever Hospital-Naval Medical Research Unit No. 3-Cairo, Egypt, from 1976 to 1996. *Am J Trop Med Hyg*. 1998;58:28-34.
- [31] Hosoglu S, Geyik MF, Balik I, Aygen B, Erol S, Aygencel TG, et al. Predictors of outcome in patients with Tuberculosis meningitis. *Int J Tuberc Lung Dis*. 2002;6:64-70.
- [32] Hosoglu S, Ayaz C, Geyik MF, Kokoglu OF, Ceviz A. Tuberculosis meningitis in adults: an eleven-year review. *Int J Tuberc Lung Dis*. 1998;2:553-57.

PARTICULARS OF CONTRIBUTORS:

1. Senior Resident, Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Sector 12, Chandigarh, India.
2. Associate Professor, Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Sector 12, Chandigarh, India.
3. Assistant Professor, Department of Neurology, Postgraduate Institute of Medical Education and Research, Sector 12, Chandigarh, India.
4. Assistant Professor, Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Sector 12, Chandigarh, India.
5. Professor, Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Sector 12, Chandigarh, India.
6. Professor and Head, Department of Radiodiagnosis and Imaging, Postgraduate Institute of Medical Education and Research, Sector 12, Chandigarh, India.
7. Professor and Head, Department of Neurology, Postgraduate Institute of Medical Education and Research, Sector 12, Chandigarh, India.
8. Professor and Head, Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Sector 12, Chandigarh, India.

NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:

Dr. Kusum Sharma,
Associate Professor, Department of Medical Microbiology, PGIMER, Sector 12, Chandigarh-160012, India.
E-mail: sharmakusum9@yahoo.co.in

FINANCIAL OR OTHER COMPETING INTERESTS: None.

Date of Submission: **Sep 26, 2014**

Date of Peer Review: **Dec 01, 2014**

Date of Acceptance: **Dec 01, 2014**

Date of Publishing: **Jan 01, 2015**